Pm8002 (Anti-PD-L1 & VEGF)

Synonyms: BNT327

For research use only. Not for use in humans.

Home Biosimilar Antibodies Immunology & Inflammation PD-1/PD-L1 inhibitor -VEGFR antibody Pm8002 (Anti-PD-L1 & VEGF)

Pm8002 is a bispecific antibody targeting both PD-L1 and VEGF-A, with potential immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities. It demonstrates promising antitumor effects in patients with previously treated platinum-resistant recurrent ovarian cancer (PROC) or cervical cancer, as well as in those with advanced solid tumors. MW : 172.48 KD.

Pm8002 (Anti-PD-L1 & VEGF)

Purity & Quality Control

Batch: A400301 Purity: 99% Protein concentration: 9.36mg/ml Endotoxin Level: ＜1EU/mg
99

Choose Selective PD-1/PD-L1 Inhibitors

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 6
PD-1/PD-L1 Inhibitor 3 13
BMS-1 13
BMS202 25
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 1
Camrelizumab (anti-PD-1) 1
AUNP-12 3
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Pm8002 is a bispecific antibody targeting both PD-L1 and VEGF-A, with potential immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities. It demonstrates promising antitumor effects in patients with previously treated platinum-resistant recurrent ovarian cancer (PROC) or cervical cancer, as well as in those with advanced solid tumors. MW : 172.48 KD.

Product Details

CAS No. N/A
Source CHO
Storage
(From the date of receipt)		 -80℃(avoid freeze-thaw cycles)

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.